Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era. But even as the billions pile up, Regeneron isn't entirely happy with ...

Bristol Myers Squibb has continued its ruthless cost-cutting push, dropping plans to commercialize a rival to Dupixent despite meeting its phase 3 goals and pumping the brakes on a would-be ...

Sanofi and Regeneron have celebrated a pair of positive clinical trials in inflammatory skin disorders with blockbuster immunology therapy Dupixent that could both lead to new indications for the ...

Chief executive Chris Viehbacher said on Biogen's results call that a plan to extend the use of the subcutaneous injector into the induction phase of treatment could be a "game changer." ...

By injecting neat or semi-dilute products at the nozzle, the innovative Knight Smart-Inject system provides instant product ...

As promised last year, Subaru has just introduced the 2025 Forester Hybrid, or the 2025 Subaru Forester e-BOXER Hybrid for Canadian consumers. As one of the last SUVs in its segment to garner a ...

Dupixent (dupilumab) was the first biologic treatment approved ... Most people are able to give themselves the injection after they learn how. The injection is typically given into a fatty area around ...

On October 14, 2024, the FDA approved a 320-mg single dose of bimekizumab-bkzx (Bimzelx; UCB) in a 2-mL prefilled syringe and autoinjector; both forms are now commercially available in the US.

You can install Opentelemetry Operator via Helm Chart from the opentelemetry-helm-charts repository. More information is available in here. WARNING: Until the ...

According to the lawsuit, Sanofi has failed to provide partner Regeneron adequate information regarding the sales of Dupixent—including agreements with payers and pharmacy benefit managers that ...

Pre-Market: 6:59:59 a.m. EST ...

After hours: 7 February at 19:49:44 GMT-5 ...